Antibiotice S.A.

BVB:ATB Stock Report

Market Cap: RON 1.7b

Antibiotice Future Growth

Future criteria checks 2/6

Antibiotice is forecast to grow earnings at 16.2% per annum.

Key information

16.2%

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth13.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updated12 Mar 2025

Recent future growth updates

No updates

Recent updates

Antibiotice (BVB:ATB) Is Paying Out Less In Dividends Than Last Year

Apr 25
Antibiotice (BVB:ATB) Is Paying Out Less In Dividends Than Last Year

Antibiotice (BVB:ATB) Will Pay A Smaller Dividend Than Last Year

Apr 04
Antibiotice (BVB:ATB) Will Pay A Smaller Dividend Than Last Year

Is Antibiotice (BVB:ATB) Using Too Much Debt?

Nov 23
Is Antibiotice (BVB:ATB) Using Too Much Debt?

Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost

Jun 07
Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost

Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump

Jan 30
Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump

We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease

Jan 13
We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely

Aug 16
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely

Is Antibiotice (BVB:ATB) A Risky Investment?

Jun 08
Is Antibiotice (BVB:ATB) A Risky Investment?

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Mar 10
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield

Feb 11
Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield

Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)

Jan 12
Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)

Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 16
Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?

Is Antibiotice (BVB:ATB) Using Too Much Debt?

Nov 24
Is Antibiotice (BVB:ATB) Using Too Much Debt?

Earnings and Revenue Growth Forecasts

BVB:ATB - Analysts future estimates and past financials data (RON Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202566798-5261N/A
12/31/2024689102-2195N/A
9/30/20246589244141N/A
6/30/20246519336161N/A
3/31/20246199626128N/A
12/31/20236158124122N/A
9/30/2023605991549N/A
6/30/2023572794071N/A
3/31/2023556653476N/A
12/31/20225055171116N/A
9/30/20224984162137N/A
6/30/20224674547112N/A
3/31/2022440354781N/A
12/31/2021379301544N/A
9/30/2021394273161N/A
6/30/2021366272660N/A
3/31/2021342264281N/A
12/31/2020347264694N/A
9/30/202035727-556N/A
6/30/202037028-2645N/A
3/31/202040332-5319N/A
12/31/201939531-4921N/A
9/30/201937135-761N/A
6/30/201938537-359N/A
3/31/201937534N/AN/AN/A
12/31/201836934N/A21N/A
9/30/201834834N/AN/AN/A
6/30/201835134N/A9N/A
3/31/201834432N/AN/AN/A
12/31/201733934N/A19N/A
9/30/201734433N/AN/AN/A
6/30/201734133N/A28N/A
3/31/201733829N/AN/AN/A
12/31/201633730N/A3N/A
9/30/201634330N/AN/AN/A
6/30/201634528N/A45N/A
3/31/201633628N/AN/AN/A
12/31/201533427N/A60N/A
9/30/201532125N/AN/AN/A
6/30/201530528N/A34N/A
3/31/201531432N/AN/AN/A
12/31/201432231N/A58N/A
9/30/201432034N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATB's forecast earnings growth (16.2% per year) is above the savings rate (6.1%).

Earnings vs Market: ATB's earnings (16.2% per year) are forecast to grow faster than the RO market (5% per year).

High Growth Earnings: ATB's earnings are forecast to grow, but not significantly.

Revenue vs Market: Insufficient data to determine if ATB's revenue is forecast to grow faster than the RO market.

High Growth Revenue: Insufficient data to determine if ATB's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ATB's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/20 02:36
End of Day Share Price 2025/07/18 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Antibiotice S.A. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vladimira UrbankovaErste Group Bank AG
Alex DodoiSSIF BRK Financial Group S.A.
Roxana DascaluSSIF IEBA Trust SA